Novo Nordisk A/S (NOVA.F)

Is Eli Lilly Stock A Sell After Its Disastrous Third-Quarter Report?

Is Eli Lilly stock a sell after third-quarter sales of its diabetes and obesity drugs missed forecasts? Is LLY stock a sell?

Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved versions of its drugs Wegovy and Ozempic. Amid shortages and rising demand for branded drugs, compounded semaglutide has gained popularity due to its affordability. However, Novo Nordisk contends that only FDA-approved versions should be available, emphasizing the safety risks associated with compounded drugs. Novo Nordisk’s Chief Financial Officer Karsten Munk Knudsen has rep

• 
  Novo Nordisk's stock hits 9-month low as 2025 guidance underwhelms

  Reuters
• 
  A new stronger Ozempic is coming. Here's what to know

  Quartz